Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin

NCT02887625 NA UNKNOWN

To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea

Details

Lead sponsor	Dr. Muhammad Abdulghani
Phase	NA
Status	UNKNOWN
Enrolment	410
Start date	2015-02
Completion	2017-05

Conditions

• Type 2 Diabetes

Interventions

• Pioglitazone plus exenatide
• insulin glargine and insulin aspart

Primary outcomes

• HbA1c — 3 years
  difference in HbA1c between the two treatment groups will be compared at 1 and at 3 years to determine efficacy and durability of each treatment

Countries

Qatar